FIELD: pharmacology.
SUBSTANCE: during the trial rabbits are given the inhibitor preparation lynestrenol in vivo endogastrically with the daily dose of 110 mkg/kg of animal body weight in the course of 14, 21 or 28 days.
EFFECT: invention makes it possible to use lynestrenol as positive control of lower activity of glycoprotein-P for prediction of inclusion of studied medicinal agents into substrates of a transporter protein.
1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| MEANS FOR REDUCTION OF GLYCOPROTEIN-P FUNCTIONAL ACTIVITY AND EXPRESSION | 2017 |
|
RU2649134C1 |
| METHOD FOR EXPERIMENTAL FINASTERIDE SIMULATION OF INDUCTION OF FUNCTIONAL ACTIVITY OF GLYCOPROTEIN-P | 2012 |
|
RU2504018C1 |
| METHOD OF DETERMINING FUNCTIONAL ACTIVITY OF GLYCOPROTEIN-P | 2015 |
|
RU2587780C1 |
| HYDROLYZATE OF TANSY FLOWERS COMPLEX POLYSACCHARIDE COMPLEX AS A GLYCOPROTEIN-P TRANSPORTER PROTEIN INHIBITOR | 2019 |
|
RU2699042C1 |
| METHOD FOR SIMULATING INHIBITION STATE OF FUNCTIONAL ACTIVITY OF GLYCOPROTEIN-P WITH DIPEPTIDYL PEPTIDASE 4 INHIBITOR | 2015 |
|
RU2602688C1 |
| METHOD FOR ASSESSING THE FUNCTIONAL ACTIVITY OF GLYCOPROTEIN-P IN THE BLOOD-BRAIN BARRIER | 2018 |
|
RU2677286C1 |
| METHOD FOR INHIBITION OF GLYCOPROTEIN-P IN AN IN VITRO EXPERIMENT | 2021 |
|
RU2779177C1 |
| METHOD FOR TREATING NEURODEGENERATIVE DISEASES | 2021 |
|
RU2777871C1 |
| ANTITUMOR COMPOSITION OF DOXORUBICIN WITH ATP INHIBITOR-DEPENDENT REVERSE CELL TRANSPORTER | 2018 |
|
RU2680834C1 |
| PHARMACEUTICAL COMPOSITION BASED ON HAEE PEPTIDE FOR TREATING NEURODEGENERATIVE DISEASES | 2019 |
|
RU2709539C1 |
